Tirzepatide for Obesity Treatment and Diabetes Prevention
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. METHODS: We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo. The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period. The three key secondary end points, which were controlled for type I error, were the percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods. RESULTS: At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo). Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001). After 17 weeks off treatment or placebo, 2.4% of the participants who received tirzepatide and 13.7% of those who received placebo had type 2 diabetes (hazard ratio, 0.12; 95% CI, 0.1 to 0.2; P<0.001). Other than coronavirus disease 2019, the most common adverse events were gastrointestinal, most of which were mild to moderate in severity and occurred primarily during the dose-escalation period in the first 20 weeks of the trial. No new safety signals were identified. CONCLUSIONS: Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prediabetes to type 2 diabetes by 66-93% compared with placebo.65,75,76”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [76]
In the citing paper
“Tirzepatide administered at doses of 5, 10, and 15 mg once weekly in adjunct with a behavioral intervention comprising an energy-deficit diet and increased physical activity appears to be even more effective, with absolute weight losses of 15.0%, 19.5%, and 20.9% after 72 weeks in the SURMOUNT-1 trial 31 that was largely maintained when treatment was continued in a subset of participants for 176”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“SURMOUNT-1 showed the NNT with tirzepatide to prevent one case of T2D was 9 patients.”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“This stepwise approach anchored in trial evidence strengthens confidence in the validity and applicability of the current results, reinforcing the role of GLP-1-based therapies beyond previously established benefits in the evolving management of cardiometabolic HFpEF.54,56-62”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [62]
In the citing paper
“the reversal in glycemic benefits in HbA1c and FSG were observed early on within 16 weeks of withdrawing tirzepatide likely due to the known direct glucose-lowering effect of tirzepatide”
From Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial (2026) · cites this paper as [18]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citation2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Self-citationLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Cited by
Items 301–400 of 443
Collazo–Clavell, M. L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2510196
Sex Differences in Cardiovascular-Related Responses to Obesity Treatment
Silver, N., Ghanta, A., Abene, J., Pinto, Y., & Chao, A. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00774-9
“[ 32] Sex-based differences were not reported for this outcome.”
Tangirala, S., Isaac, S., Gehad, Y., Roquefort, F., Gabrieli, P., Leong, A., Mercader, J. M., Sevilla-González, M. D. R., Baldini, F., Miller, G. W., et al. (2025) · medRxiv · doi:10.1101/2025.09.26.25336579
“Nonetheless, head-to-head evidence that reduction beyond what is observed with single agonist GLP1-based interventions is a strong case for the possibility for improvement, such as data emerging from the multiple-agonist GLP1 drugs 25,26 , such as tirzepatide 27 .”
TARGETING MULTIPLE PATHWAYS WITH ONE MOLECULE: THE THERAPEUTIC VERSATILITY OF TIRZEPATIDE
Jędrzejewska-Rzezak, P., Żuczek, A., Dyndał, K., Broda, M., Żuczek, O., Urbańska, K., Szczap, I., Hawryluk, A., Marzec, K., & Mokrzycka, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3902
Reducing the risk of developing diabetes
Honka, H., & Pimiä, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00291-0
Coleman, C. D., Kiel, J., Palacios, O. M., Bell, M., Wilcox, M. L., Maki, K. C., Unick, J. L., & Jonnalagadda, S. S. (2025) · Clinical Obesity · doi:10.1111/cob.70046 · Cited by 1
Xiao, Y., Chen, J., Guo, M., Liu, X., Xu, X.-M., Yan-qun, L., Jiang, Z., Xu, Y., & Deng, C. (2025) · Research Square · doi:10.21203/rs.3.rs-7103001/v1 · Cited by 1
EndoCompass Project: Research Roadmap for Diabetes, Obesity, and Metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000549194 · Cited by 1
“Recent pharmacologic interventions with incretin derivatives have shown that, by obtaining substantial and sustained weight reduction, a markedly lower risk of progression to T2D is observed than with placebo [138].”
Farley, B., Radetich, E., D’Alessandro, J. S., & Bulaj, G. W. (2025) · Healthcare · doi:10.3390/healthcare13243220 · Cited by 2
Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
Kwak, K. H., & Jung, C. H. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2803 · Cited by 1
“Semaglutide 2.4 mg, the most recent single peptide targeting the GLP-1 receptor, produces approximately 15% weight reduction over 68 weeks [6], whereas tirzepatide, a dual GLP-1/ GIP agonist, achieves nearly 20% reductions [7], approaching outcomes typically observed with bariatric procedures.”
InfluentialEquity, Diversity and Inclusion is essential for rigorous science and good for health
Pritlove, C., Herder, C., Krook, A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06629-7
“Clinical trials, too, are changing, with nearly half of participants in SURMOUNT-1 (evaluating tirzepatide for obesity) identifying as Hispanic or Latino and with specific consideration given to ensuring that US enrolment was representative of the American population living with obesity [17].”
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8270 · Cited by 2
Novel Therapeutic Strategies for Obesity-Related Glomerulopathy
Liu, Y., Eirin, A., & Lerman, L. O. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01357-0 · Cited by 2
“Three years of tirzepatide in individuals with obesity and prediabetes led to sustained weight-loss and a substantially reduced risk of progressing to T2DM [55].”
Селюкова, Н. Ю., Lurin, I. A., Tyzhnenko, T., & Misiura, K. V. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.8.2025.1661
Pharmacologic glycemic management of type 2 diabetes
Mourelatou, N. G., & Rebelos, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00284-3
Kołodziej, K. E., Chrobak-Bień, J. Z., Wcisło, T., Plewka, M., & Borowiak, E. (2025) · Pielegniarstwo XXI wieku / Nursing in the 21st Century · doi:10.12923/pielxxiw-2025-0041
Chen, J., Cao, Q., Su, X., & Lu, X. (2026) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01169-7
Tonnesen, P. T., Olesen, K. K. W., Gyldenkerne, C., Hansen, M. K., Stødkilde-Jørgensen, N., Thrane, P. G., Andersen, M. H., Poulsen, P. L., Thomsen, R. W., Sattar, N. A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03085-4 · Cited by 1
“Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA, reduced the progression from prediabetes 5.7%−6.4% to type 2 diabetes as compared with placebo over a three-year period (1.3% versus 13.3%; HR 0.07; 95% CI 0.0-0.1) in the SURMOUNT-1 trial [33].”
InfluentialIslam, B. N., Nguyen-Gomez, A., Williams, K., Curry, K., Khandekar, N. S., Chieppa, M., Xin, W., Pizarro, T. T., Wang, R., & Cominelli, F. (2026) · Gut · doi:10.1136/gutjnl-2025-337537 · Cited by 1
Stafford, J. M., Jaeger, B. C., Casanova, R., Demesie, Y. N., Wells, B., & Bancks, M. P. (2026) · Diabetes Care · doi:10.2337/dc25-2268
Iglesias, P. C. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02828-0
Modifiable Factors Affecting the Postprandial Glycemic Response
Wu, Y., McLaughlin, T., Gorgani, S., Scheideman, A. F., Shao, M. M., Hislop, B. D., Hoang, K., Perelman, D., McGinity, C., Rodgar, M., et al. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261418614 · Cited by 2
El‐Amawy, H. S. (2026) · Anais Brasileiros de Dermatologia (Versão em Português) · doi:10.1016/j.abdp.2026.501255 · Cited by 1
Guo, W., Wang, M., Shin, J., Li, F., O'Brien, E. C., Glover, L. M., Bortfeld, K., Zhao, A., McDevitt, R. C., Kalapura, C., et al. (2026) · medRxiv · doi:10.64898/2026.02.18.26346594
Adverse events associated with tirzepatide: a focus on subgroup-specific differences
Yu, Z., Qi, Y., Gan, Q., Wu, G., Zhang, X., Jiang, C., & Li, J. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01105-3 · Cited by 3
“Subsequently, tirzepatide demonstrated substantial and lasting weight reductions in obese individuals over a 72-week span, leading to the approval of another product (ZEPBOUND), specifically for weight management in November 2023 [11, 12].”
Medikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
Is pharmacotherapy ready to redefine the state of the art in obstructive sleep apnea care?
Johnston, E. K., Bird, E. M., Malhotra, A., & Harding, C. D. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2634201
“In a Phase III trial of 2539 adults with obesity, tirzepatide produced up to 20% weight loss and sustained diabetes-free status for over 3 years [8].”
Sanyal, A. J., Parmar, K., de Oliveira, A. B. S., Jahagirdar, V., & Smirnova, E. (2026) · Research Square · doi:10.21203/rs.3.rs-8342646/v1
Ayati, A., Watanabe, A. H., Guillot, J., Azzam, S., Zhang, X., Chaudhri, E., Vendetti, M. L., Fernandes, G. F., Rudrapatna, V. A., & Ge, J. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00057-z
“For MASH, emerging agents (GLP-1 – based therapies and FGF21 analogs) improve intermediate endpoints; however, no drug has yet demonstrated bene fi t on hard clinical outcomes 21 – 23 .”
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01446-x
Heerspink, H. J. L., van Raalte, D. H., Tuttle, K., Cherney, D. Z. I., Bjornstad, P., Cao, D., Dimitriadis, G. K., Linetzky, B., Jouravskaya, I., Bunck, M. C. M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70622 · Cited by 2
Self-citationSOUZA, M. M. X. D., Amaral, M. J. M., & Lima, L. C. V. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70642
Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure
Nicze, M., Borówka, M., Dec, A., Bułdak, Ł., Bołdys, A., & Okopień, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062539 · Cited by 7
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
“Reductions in T2D diagnosis have also been observed with semaglu-tide with an 80% reduction in incident diabetes in a comorbid population [22], and similarly with tirzepatide with a reduction in incident diabetes by 90% [11].”
InfluentialState of the art overview wearable glucose sensors based on nanosheets
Li, K., Liu, C., Li, Q., Tian, Z., Shi, H., Li, H., & Zhang, S. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.100751
Self-citationLandin‐Olsson, M., Ekholm, B., Erlanson‐Albertsson, C., & Holm, C. (2026) · Journal of Dairy Science · doi:10.3168/jds.2025-28153
Collaborators, G. U. H. D., Mouhanna, F., Kahn, E., Schmidt, C. A., McHugh, T. A., Baumann, M. M., Kelly, Y. O., Motte‐Kerr, W. L., Cogen, R. M., Dai, X., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04795-y · Cited by 1
“This class of drugs also reduced the incidence of comorbidities such as type 2 diabetes [96] and cardiovascular events [97, 98].”
Kartiko, D. C., Rejeki, P. S., Indarto, D., Subagio, I., Hartati, S. C. Y., Orhan, B. E., Nurwati, Y., & Pranoto, A. (2026) · Physical Education Theory and Methodology · doi:10.17309/tmfv.2026.2.16
Mallette, J. H., Speed, J. S., Lirette, S. T., Moore, D., & Clemmer, J. S. (2026) · Obesity · doi:10.1002/oby.70180
“In 2023, tirzepatide became the first dual GLP-1RA and glucose dependent insulinotropic polypeptide receptor agonist approved for chronic weight management, with weight loss of up to 20% [10, 11].”
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Self-citationМамедов, М. Н., Друк, И. В., & Akhundova, H. R. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6812
Lin, C., Chen, W., Liu, S. X., Cao, B., Ge, Y., Li, Y., Liu, Y., Guo, T., Xu, J., & Wang, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-115236
Johansson, E., Wilding, J. P. H., Upadhyay, N., van Hest, N., Kirk, M., Spaepen, E., Zimner‐Rapuch, S., Annemans, L., & Bays, H. E. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2646078 · Cited by 1
Self-citationFrom Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
“中枢作用抑制食欲 [ 10 ] 。这些作用机制使得 GLP-1R 激动 剂不仅具有良好的降糖效果 , 还具备减重 、 心血管保护等 额外获益 [ 11 ] 协同的治疗新基准 [ 12 , 13 ] 。 2025 年 6 月国产全球首个获批 的胰高血糖素受体 GCGR/GLP-1R 双靶减重药物玛仕度 肽上市用于长期肥胖患者的体重控制 [ 14 ] 。 在此基础上 , GLP-1R/GIPR/GCGR 三重激动剂 ( 如瑞 他鲁肽 ) 的研发进一步推动了疗效边界。胰高血糖素受体 ( Glucagon Receptor , GCGR ) 激动具备促进肝脏消耗 、 提高 基础代谢率的能力 ,…”
Risk Factors and Outcome in Living Kidney Donors: A Narrative Review
Discălicău, L.-G., Baston, C., Sorohan, B. M., Moldoveanu, O., Margaritis, S., Vișinescu, P.-M., & Sinescu, I. C. (2026) · Kidney and Dialysis · doi:10.3390/kidneydial6020028
“Although these therapies have not been specifically studied in living kidney donors, they may represent promising tools for metabolic optimization before and after donation [10,11,31,32].”
Annemans, L., Johansson, E., Spaepen, E., van Hest, N., Grist, J., Zimner‐Rapuch, S., & Wilding, J. P. H. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2646079 · Cited by 1
Self-citationAnti-GIP antibodies and future diabetes related risk: an eight-year prospective cohort study
Hashimoto, T., Ohtake, N., Okamoto, T., Zhang, B., Yoshida, Y., Takizawa, H., Yamaga, M., Yoshida, T., Kajiyama, A., Yagihashi, T., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1811527
Fang, Q., Zhu, Y., Rao, M., & Liu, P. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1752341 · Cited by 2
“Tirzepatide has demonstrated consistent and clinically meaningful weight reduction across multiple studies, establishing it as one of the most promising non-surgical pharmacologic options for obesity management (15, 25).”
Pineda-Wieselberg, R. J., Soares, A. H., Napoli, T. F., Scalissi, N. M., & Salles, J. E. N. (2026) · Nutrients · doi:10.3390/nu18091419
“These values were compared with reference benchmarks from pivotal trials/summary [10–19] estimates (e.g., 14.9% for semaglutide; 8.54% for naltrexone/bupropion; 11.6% for sibutramine; 6.3% for topiramate; 19.7% for tirzepatide) to contextualize the real-world performance of these subjects.”
InfluentialKim, Y., Kim, K. H., Lee, S. H., Moon, Y., Oh, Y., & Seo, K. W. (2026) · Journal of Metabolic and Bariatric Surgery · doi:10.17476/jmbs.2026.15.1.10 · Cited by 1
“Three-year data for tirzepatide in adults with obesity and prediabetes indicate sustained weight loss and a reduced risk of progressing to T2D [11].”
Robinson, R., Sarkar, T. D., Moore, S., & Malhotra, A. (2026) · Current Sleep Medicine Reports · doi:10.1007/s40675-026-00373-z
Sattar, N. A., Tchang, B. G., Vincent, R. P., Wang, H., Murphy, M., Dunn, J. P., Dimitriadis, G. K., & Brumm, J. F. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02883-7 · Cited by 1
“The SURMOUNT-1 study evaluated the efficacy and safety of tirzepatide in adults with obesity or overweight who did not have diabetes and showed that tirzepatide led to substantial and sustained reductions in body weight [ 24 ].”
InfluentialManagement kardiovaskulärer Erkrankungen bei Adipositas
Baessler, A., Zurkan, D., Bischoff, G., Esefeld, K., Hümmelgen, M., Aberle, J., Wienbergen, H., Blüher, M., Werner, N., Müller, O. J., et al. (2026) · Die Kardiologie · doi:10.1007/s12181-026-00813-8 · Cited by 1
Liu, C.-Y., Yu, H.-I., Tsai, C.-F., Wu, C.-Y., & Yang, H. (2026) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2026.152995 · Cited by 1
Bauer, E. (2026) · CME · doi:10.1007/s11298-026-4619-y
Jang, S., Ma, S., Hsia, D. S., Cossen, K., Haynes, D., & Bensignor, M. O. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01873-5
Adipositas und Diabetes mellitus Typ 2 (Update 2026)
Brix, J. M., Clodi, M., Harreiter, J., Hoppichler, F., Fw, K., Itariu, B.-K., Parzer, V., Resl, M., Schindler, K., Toplak, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02706-y
“In der Verlängerung der Surmount 1-Studie über 3 Jahre konnte eine Therapie mit Tirzepatid bei Menschen mit Adipositas und Prädiabetes die Inzidenz von Typ-2-Diabetes um 93% reduzieren [4].”
Liu, H., Tang, M., Xiao, L., Tian, Y., Yao, C., & Ma, Y. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/4664479
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-3375
Tirzepatide data: safety first is safety always!
Janić, M., Rabbani, S. A., El‐Tanani, M., Rangraze, I. R., Janež, A., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2681511
TIRZEPATIDA E OS RISCOS DO USO SEM PRESCRIÇÃO MÉDICA
Silva, B. E., Alves, N. D., Francelino, J. D. S., Spaziani, A. O., Eleutério, B. M. G., da Silva, F. S., Gonzaga, D. M. I. D. S., & Franco, R. F. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n6-005 · Cited by 1
Anti-obesity medications impacting the eye: An emerging concern - a narrative review
Khullar, S., Morya, A. K., Aggarwal, S., Singh, A., Sisodiya, P., & Morya, R. (2026) · World Journal of Methodology · doi:10.5662/wjm.118520
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review
Fuentes‐Mendoza, J. M., Concepción‐Zavaleta, M. J., Dueñas, L. G. D., Jara-Pianto, J. M. J., Sierra-Martel, J. A., Medina-Angulo, C. A., Flores, H. M. V., Mendoza-Godoy, J. J., Zavaleta‐Gutiérrez, F. E., & Paz‐Ibarra, J. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.118730
Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome
Liao, X. C., Huang, T., Hong, D. S., & Luo, L. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag152
“These weight and metabolic improvements are clinically significant and may reduce future risk of type 2 diabetes and cardiovascular disease [15, 16].”
Budini, B., Lee, A., Luo, S., Tam, M., Stead, I., Akrami, A., Vidal‐Puig, A., & Park, A. J. (2026) · Proceedings of The Nutrition Society · doi:10.1017/s0029665126102444
Umińska, J. M., Ratajczak, J. M., Niezgoda, P., Gajda, R., Szarpak, Ł., Kubica, J., & Navarese, E. P. (2026) · Obesities · doi:10.3390/obesities6030038 · Cited by 3
“The aim of this review was to synthesize the available direct comparative evidence on tirzepatide versus semaglutide, while incorporating selected secondary and contextual analyses that help clarify how the current comparative hierarchy should be interpreted [12–20].”
Pharmacological treatment of obstructive sleep apnea syndrome
Tardov, M. V., Boldin, A. V., Афанасьевич, Ф. А., Kotidis, I. M., Бокова, И. А., Tardova, V. M., & Bokova, O. A. (2026) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202612605248 · Cited by 1
Sun, X., Zhou, J., Chen, Z., Xin, Z., Ren, J., Zheng, Y. N., Wang, J., Zhang, J. Q., Zhang, Y., Liu, L., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1850839
Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD
Varghese, P., Elder, R. W., Vinocur, J. M., Spatz, E. S., Shabanova, V., McCollum, S., Harper, M., & Pastor, T. A. (2026) · Cardiology in the Young · doi:10.1017/s1047951126113109 · Cited by 1
Dziewierz, A., Kulicka, N., Stolarska, K., Ahmatovic, A., Domienik‐Karłowicz, J., Rulkiewicz, A., & Siudak, Z. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71017 · Cited by 1
Rutter, M. K., Mount, J., GIBSON, J. M., Webb, J., Marler, C., Reed, C., Gore, M., Ye, W., Valderas, E. G., Wilding, J. P. H., et al. (2026) · Obesity · doi:10.1002/oby.70247
Self-citationObesity medications versus metabolic bariatric surgery: the debate goes on
Tan, T. M.-M. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00124-5
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
“As a result, tirzepatide, a dual GLP-1/GIP receptor co-agonist, has secured regulatory approval for managing T2D and obesity [23,24].”
Frier, K. C., Dietl, M., Aronson, S., Dhani, J. S., James, K., Betensky, D. J., Selzer, F., Losina, E., Katz, J. N., Kim, J. S., et al. (2026) · ACR Open Rheumatology · doi:10.1002/acr2.90070
GLP-1 therapies for obesity: mechanisms, outcomes, and regulatory challenges
Emos, D. D. O., González, J. D. J. M., Diani, L. M., Pinhel, M. A. D. S., Watanabe, L. M., Leca, A. V., Brandao, C. F. C., Nonino, C. B., & Noronha, N. Y. (2026) · Academia Drug Development and Pharmacotherapy · doi:10.20935/acaddrug8360
Shil, K. K. (2026) · European journal of medical research · doi:10.1186/s40001-026-04862-3
GLP-1 medications: use and interest in a representative survey of Finns
Jallinoja, P. T., Pietiläinen, K. H., & Chang, V. W. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02149-5 · Cited by 2
GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways
Lindquist, P., Dijkhof, L. R. H., Drzazga, A. K., Sabatier, P., Stępniewski, T. M., Granlund, L., Lechner, M. Y., Zhong, Y., Gasbjerg, L. S., Hartmann, B., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.003
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
Chao, A. M., Asante, R., Sersah, M. E., Jahangir, U. A., Peary, A., & Kudaya, D. Q. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70162
Zgolli, F., Daly, W., Aouinti, I., Dahmani, I., Hela, H., Kooli, H., Kastalli, S., & Aïdli, S. E. (2026) · Therapies · doi:10.1016/j.therap.2026.06.003
Kitamoto, T., Yoshino, M., Shingaki, T., Oura, T., Valderas, E. G., & Dunn, J. P. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2695047
“SURMOUNT-4 demonstrated maintenance of initial weight reduction with tirzepa-tide for 88 weeks, and the 3-year extension of SURMOUNT-1 demonstrated sustained weight reduction and reduced T2D risk with tirzepatide compared with placebo 10,30 .”
Jiang, Y., Meng, W., Shi, X., Gao, S., & Zhan, P. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100018
Spiazzi, B. F., Zingano, C. P., Colpani, V., & Gerchman, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113431 · Cited by 3
Breakthrough drugs in the treatment of hypertension-related disease
Hoshide, S., Mogi, M., Shibata, S., Kishi, T., Usui, I., Ando, H., Nakagami, H., Nishiyama, A., Kario, K., & Japanese Society of Hypertension (JSH) Working Group on Emerging Pharmacological Therapies for Hypertension Management (2026) · Hypertension Research · doi:10.1038/s41440-026-02725-2
“In those trials, blood pressure reduction and weight loss were dose-dependent, with the maximum dose of 15 mg/week resulting in a 6-9 mmHg reduction in systolic blood pressure and a 15 – 18% reduction in body weight [48 – 51].”
Sargis, R. M., Reutrakul, S., Trasande, L., & Nadal, Á. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01635-4
“…sugars, but that also reduce microvascular complications [ 94 – 97 ], address common comorbidities and predisposing factors (e.g., obesity, MASLD, obstructive sleep apnea, hypertension) [ 98 –103], reduce prediabetes-to-T2D progression [ 98 , 104], and improve cardiovascular outcomes [105– 109 ].”
Muscle in fat trouble: The rise of IMAT in metabolic and musculoskeletal disease
Weik, V., Birkenfeld, A. L., Peter, A., Weigert, C., & Dreher, S. I. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102424 · Cited by 1
“These mono-und dual-incretin receptor agonists have a strong SAT and VAT lowering potential and it is plausible that these effects extend to IMAT [83,84].”
EndoBridge 2025: pearls and highlights
Yıldız, B. O., Armenti, M., Brandi, M. L., Carey, J., Carling, T., Ciudin, A., Dhatariya, K., Fountas, A., Frühbeck, G., Goulis, D. G., et al. (2026) · HORMONES · doi:10.1007/s42000-026-00804-0 · Cited by 1
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Pastika, L., Patlatzoglou, K., Sieliwończyk, E., Barker, J., Zeidaabadi, B., McGurk, K. A., Barreto, S. M., Camelo, L. D. V., Khan, S. N., Scott, W. R., et al. (2026) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztag118
“56–59 Fourth, single-lead models could be deployed on wearable devices to further enhance screening.”
Babazadeh, D., Zhong, H., & Steinberg, F. M. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101753 · Cited by 1
Campbell, C., Mansoor, M., Eley, C., Nann, S. D., & Puhalla, H. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.07.012 · Cited by 1
Kushner, P. R., & Michos, E. D. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049727 · Cited by 2
“10 In the pivotal phase 3 trials of semaglutide and resmetirom for MASH, the placebo-adjusted number of participants who had reduction in liver fibrosis without worsening of steatohepatitis was only 14.4% 11 and 10.0% to 11.7% (dose dependent), 12 respectively.”
InfluentialMohamed, Z. I., Shidane, A. A., Abdiasis, A. M., Hussein, M. H., Ibrahim, A. O., Abdi, A. A., Hashi, K. I., Mohamud, M. A., & Mohamed, A. J. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70298
Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review
Garcia, C. C., Moryousef, J., Pinthus, J. H., & Leong, D. P. (2026) · Cancers · doi:10.3390/cancers18152465
“In addition, these agents improve glycemic control and several cardiometabolic risk factors, while semaglutide has also been shown to reduce major adverse cardiovascular events in individuals with overweight and established cardiovascular disease [99–102].”
Tirzepatide for Severe Obesity in Adolescents Without Diabetes
Yehia, R., Patel, P., Sousa, E., & Vidmar, A. P. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.07.013
Acute pancreatitis and its impact on mental health
Hoard, M., & Smith, Z. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30263-3.00004-x
Pérez‐Pevida, B., Santana, M. S., Arriola, C. L., Maldonado, A., Clérigo, B., Ruiz, C., Higueruela, C., Ballesteros-Pomar, M. D., Lesmes, I. B., & Rodríguez, M. M. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.105005 · Cited by 1
Obstructive sleep apnea pharmacology
Sunwoo, B. Y., Schmickl, C. N., & Malhotra, A. (2026) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2026.2695024
“86,87”
Inamine, S., & Uesato, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71190 · Cited by 1
Type 2 diabetes prevention across the life course
Wang, Y., Sargent, J. L., Mathieu, C., Arreola, E. V., Perreault, L., Loos, R. J. F., Lim, L., Sandforth, L., Hanson, R. L., Kullmann, S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04550-z · Cited by 1
Self-citation
Metadata
- Authors
- Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., Bunck, M. C., Ahmad, N. N., & Jouravskaya, I.
- Affiliations
- University College Dublin (IE)
- Eli Lilly, Indianapolis
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-03-06
- Volume
- 392
- Issue
- 10
- Pages
- 958-971
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404310616
- Semantic Scholar
- 6522eecd15e4fbb48021d492e79ee341ffc3540a
- Cited by
- 462
- References
- 41
- Citations by year
- 2026: 239 · 2025: 220
- FWCI
- 130.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- tirzepatide, obesity, prediabetes, type 2 diabetes prevention, weight loss, GIP/GLP-1 receptor agonist, long-term safety, diabetes onset, adverse events, drug discontinuation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Middle Aged, Obesity, Prediabetic State, Weight Loss, Disease Progression, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.